| Oct 31 |
Regeneron Pharmaceuticals Non-GAAP EPS of $12.46 beats by $0.75, revenue of $3.72B beats by $50M
|
| Oct 31 |
Regeneron Reports Third Quarter 2024 Financial and Operating Results
|
| Oct 30 |
Regeneron Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 28 |
Regeneron to Report Q3 Earnings: What's in the Offing?
|
| Oct 28 |
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
|
| Oct 28 |
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
| Oct 28 |
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
|
| Oct 28 |
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
|
| Oct 26 |
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
|
| Oct 25 |
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
|
